Helus Pharma Inc. (HELP) — the Nasdaq-listed clinical-stage neuropsychiatry developer formerly known as Cybin Inc. — is covered almost entirely by bullish research. Nine recent, individually attributed price targets were reviewed, ranging from roughly $15 to $70, which averages to about $40 and rounds to a $40 central target.
The spread is striking. H.C. Wainwright's Patrick Trucchio reiterated a $70 target (October 2026), while TD Cowen's Ritu Baral lifted the firm's view to $62 from $8 in August 2026, and Bloom Burton stood at $47. At the more cautious end, Alliance Global Partners cut its target to $15 from $30 (July 2026), Wells Fargo's Benjamin Burnett raised his to $22 from $16 (October 2026), and Jefferies' Andrew Tsai maintained $22. Barclays initiated coverage at $35 in September 2026, and Canaccord Genuity reiterated $42. Guggenheim last carried $48.
All nine ratings are Buy or equivalent, producing a "Strong Buy" style consensus, but the target dispersion reflects genuine disagreement about the probability of Phase 3 success, the commercial opportunity, and financing risk. This wide range means the $40 average is a useful midpoint, not a guarantee.
HELP last traded around $9.37, giving the company a market value near $685 million and a 52-week range of roughly $3.76 to $15.15. Reaching $40 would require an advance of about 327%, a very large move that would depend almost entirely on clinical data rather than ordinary valuation drift.
The path centers on HLP003, a deuterated psilocybin analog in the Phase 3 APPROACH trial for adjunctive treatment of major depressive disorder (MDD). Management completed enrollment in July 2026 and expects topline data in Q4 2026. Positive results could trigger a sharp repricing toward, and potentially beyond, several analyst targets. A second program, HLP004 (a deuterated DMT candidate for generalized anxiety disorder), is expected to begin a Phase 2 monotherapy trial in Q1 2027. The company holds FDA (Food and Drug Administration) Breakthrough Therapy designation for its lead program.
Analysts' bullish views rest on several pillars: strong Phase 2 efficacy and durability for HLP003, a favorable safety and tolerability profile, an adjunctive positioning that avoids washing patients off existing antidepressants, and a large unmet need in a disease affecting roughly 22 million U.S. adults. Management has cited about $165 million in cash and equivalents, a runway it describes as sufficient into 2027, and recent capital raises have retired debt. A newly appointed CEO and board chair, plus clinical catalysts and potential large-pharma interest in the psychedelic neuropsychiatry space, add optionality.
The principal obstacle is binary: if APPROACH data disappoint, the stock could fall sharply, and a $40 target would become immaterial. The company is pre-revenue and posts meaningful losses — about a $171 million net loss and negative EPS (earnings per share) on a trailing basis — so valuation depends on future outcomes, not current earnings. Dilution risk, competition in depression and anxiety treatment, regulatory uncertainty, and the co-founders' recent exit from executive roles all weigh on sentiment. The very wide analyst range, including a $15 target barely above the current price, underscores how much rests on a single readout.
HELP trades below its 52-week high near $15.15, a zone that acted as prior resistance, while the $3.76 low marks the lower bound of the long-term range. The stock recently bounced off the $8.75–$8.96 area and reclaimed the $9 handle, putting the $10 psychological level and then the mid-teens as the next reference points. A decisive move through the $15 area would clear the range's upper resistance, though reaching $40 would still require a further multi-fold advance well beyond any current technical milestone.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual analysts may use different assumptions. For HELP, the most important near-term items are the Q4 2026 APPROACH topline readout for HLP003, the company's next quarterly results and cash-burn commentary, any updated runway guidance, the planned Q1 2027 start of the HLP004 Phase 2 monotherapy study, and additional safety and durability data from the EXTEND study. Analyst revisions around the data readout will likely drive the widest swings in the price target range.
For traders tracking volatile, catalyst-driven names like HELP, Tickeron's AI Daily Buy/Sell Signals offer an automated layer of monitoring. The system uses artificial intelligence to continuously scan thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. Traders can use it to discover new opportunities, keep an eye on existing positions, and spot changing trends more efficiently than manual screening alone. Consider exploring the signals alongside your own research as you evaluate the HELP setup.
Whether Helus Pharma can reach $40 depends overwhelmingly on the upcoming Phase 3 APPROACH data for HLP003. The $40 figure is an average of nine bullish analyst targets spanning $15 to $70, and it implies a roughly 327% rise from the current $9.37 price — a move that only positive pivotal data, followed by continued pipeline progress toward an NDA (New Drug Application) filing targeted for 2028, would plausibly support. Strong Phase 2 results, a large unmet need, and a bolstered balance sheet argue in its favor, while binary clinical risk, pre-revenue losses, and dilution risk argue for caution. The unusually wide analyst range is itself the key message: the range of credible outcomes is broad, and investors should weigh the data readout, cash runway, and analyst revisions above any single price target.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.